Article Text

Download PDFPDF

Extended report
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
  1. A Kavanaugh1,
  2. D Gladman2,
  3. D van der Heijde3,
  4. O Purcaru4,
  5. P Mease5
  1. 1Division of Rheumatology, Allergy and Immunology, UCSD, San Diego, California, USA
  2. 2Division of Health Care & Outcomes Research, Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
  3. 3Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
  4. 4UCB Pharma, Brussels, Belgium
  5. 5Swedish Medical Center and University of Washington, Seattle, Washington, USA
  1. Correspondence to Professor Arthur Kavanaugh, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, 9500 Gilman Drive, MC 0943, La Jolla CA 92037-0943, USA; akavanaugh{at}


Objectives To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA).

Methods RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed the impact of PsA on paid work and household productivity, and participation in social activities during the preceding month. WPS responses were compared between treatment arms using a non-parametric bootstrap-t method.

Results At baseline, 56.6%, 60.1% and 61.5% of placebo, CZP 200 mg Q2W and CZP 400 mg Q4W patients were employed. By week 24, employed CZP patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05). Within the home, by week 24, CZP patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05). CZP patients also reported fewer days with reduced household productivity or days lost for participation in family, social and leisure activities. Improvements with CZP were seen as early as week 4 and continued to week 24.

Conclusions CZP treatment significantly improved productivity at paid work and within the home, and resulted in greater participation in social activities for PsA patients.

Trial registration number NCT01087788.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.